Overview

A Study of LY8888AX in Participants Using a Connected Insulin Management Platform

Status:
Not yet recruiting
Trial end date:
2024-04-15
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess participant adherence and glucose control while using a connected insulin management platform. Approximately 50 participants will be enrolled in each country.
Phase:
N/A
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Insulin Lispro
TEMPO